324 related articles for article (PubMed ID: 12464961)
1. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
Sturm G; Kränke B; Rudolph C; Aberer W
J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
[TBL] [Abstract][Full Text] [Related]
2. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
3. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
4. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
5. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
6. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy.
Blaauw PJ; Smithuis OL; Elbers AR
J Allergy Clin Immunol; 1996 Jul; 98(1):39-47. PubMed ID: 8765816
[TBL] [Abstract][Full Text] [Related]
7. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy against hymenoptera venom: report of ten patients].
Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
[TBL] [Abstract][Full Text] [Related]
9. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
10. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
11. Continuous immunotherapy for hymenoptera venom allergy using six month intervals.
Baenkler HW; Meusser-Storm S; Eger G
Allergol Immunopathol (Madr); 2005; 33(1):7-14. PubMed ID: 15777517
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
Müller U; Helbling A; Berchtold E
J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
[TBL] [Abstract][Full Text] [Related]
13. [Safety of rush immunotherapy with Hymenoptera venom].
Sánchez-Morillas L; Reaño Martos M; Rodríguez Mosquera M; Iglesias Cadarso A; Domínguez Lázaro AR
Allergol Immunopathol (Madr); 2005; 33(4):224-7. PubMed ID: 16045862
[TBL] [Abstract][Full Text] [Related]
14. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
16. Ultrarush immunotherapy in patients with Hymenoptera venom allergy.
Ruëff F; Przybilla B
J Allergy Clin Immunol; 2001 May; 107(5):928-9. PubMed ID: 11344369
[No Abstract] [Full Text] [Related]
17. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
[TBL] [Abstract][Full Text] [Related]
18. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.
Birnbaum J; Charpin D; Vervloet D
Clin Exp Allergy; 1993 Mar; 23(3):226-30. PubMed ID: 8472191
[TBL] [Abstract][Full Text] [Related]
19. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy.
Kochuyt AM; Stevens EA
Clin Exp Allergy; 1994 Jan; 24(1):35-41. PubMed ID: 8156444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
